Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873776 | 0.94 | SMPD1 (0.70) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL17769825 | 0.93 | MAPT (0.61) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL340393 | 0.92 | SMN1; SMN2 (0.72) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL30141105 | 0.91 | KMT2A (0.62) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL3960907 | 0.91 | KMT2A (0.62) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL11286951 | 0.90 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL2063068 | 0.90 | SMN1; SMN2 (0.73) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL12310508 | 0.89 | SMN1; SMN2 (0.60) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL242563 | 0.87 | MRGPRX4 (0.77) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL27881765 | 0.87 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | LOMOND THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| CN-118076605-A | Substituted 1H-pyrazolo [4,3-c ] quinolines, methods of preparation and uses thereof | 洛蒙治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240124938-A1 | VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2024-04-18 | — | — | US | disclosed |
| EP-4045511-A1 | VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-08-24 | — | — | EP | disclosed |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| WO-2021074392-A1 | VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-04-22 | — | — | WO | disclosed |
| US-20190263782-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2019-08-29 | — | — | US | disclosed |
| US-10344015-B2 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180118716-A1 | Chemical Process | GENZYME CORPORATION (US) | 2018-05-03 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| EP-0931119-B1 | CHIRAL COMPOUNDS WITH LIQUID CRYSTALLINE NATURE AND FERROELECTRIC LIQUID CRYSTAL DEVICE ADOPTING THE SAME | SAMSUNG DISPLAY DEVICES CO LTD (KR) | 2001-12-05 | — | — | EP | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0931119-A1 | CHIRAL COMPOUNDS WITH LIQUID CRYSTALLINE NATURE AND FERROELECTRIC LIQUID CRYSTAL DEVICE ADOPTING THE SAME | SAMSUNG DISPLAY DEVICES CO., LTD. (KR) | 1999-07-28 | — | — | EP | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5755997-A | Chiral compounds with liquid crystalline nature | SAMSUNG DISPLAY DEVICES CO., LTD. (KR) | 1998-05-26 | — | — | US | disclosed |
| WO-1998014529-A1 | CHIRAL COMPOUNDS WITH LIQUID CRYSTALLINE NATURE AND FERROELECTRIC LIQUID CRYSTAL DEVICE ADOPTING THE SAME | SAMSUNG DISPLAY DEVICES CO., LTD. (KR) | 1998-04-09 | — | — | WO | disclosed |
| US-5686406-A | Vanillic acid ester perfuming agents | RHONE-POULENC CHIMIE (FR) | 1997-11-11 | — | — | US | disclosed |
| EP-0613879-A1 | PHELLODENDRINE ANALOGS AND ALLERGY TYPE IV SUPPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1994-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | NPC1 3532/4885RAB9A 1591/4885SMN1; SMN2 3955/4885 |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | NPC1 3167/4885RAB9A 537/4885SMN1; SMN2 4490/4885 |
| US-20240124938-A1 | VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS | LIG4, PCNA, ERCC5 | NPC1 4828/4885RAB9A 4245/4885SMN1; SMN2 3744/4885 |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | FLT3, PDXK, PHKG1 | NPC1 2810/4885RAB9A 2667/4885SMN1; SMN2 3960/4885 |
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | NPC1 3167/4885RAB9A 537/4885SMN1; SMN2 4490/4885 |
| US-20190263782-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | NPC1 3167/4885RAB9A 537/4885SMN1; SMN2 4490/4885 |
| US-10344015-B2 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | NPC1 3160/4885RAB9A 597/4885SMN1; SMN2 4527/4885 |
| US-20180118716-A1 | Chemical Process | CYP3A4, CYP3A5, CYP3A7 | NPC1 2914/4885RAB9A 560/4885SMN1; SMN2 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.